RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
InnoCare Pharma Stock

InnoCare Pharma Equity 2024

InnoCare Pharma Equity

7.6 B CNY

Ticker

9969.HK

ISIN

KYG4783B1032

WKN

A2PVC2

In 2024, InnoCare Pharma's equity was 7.6 B CNY, a 35.55% increase from the 5.6 B CNY equity in the previous year.

InnoCare Pharma Aktienanalyse

What does InnoCare Pharma do?

InnoCare Pharma Ltd is a biopharmaceutical company based in China, focused on researching, developing, and marketing novel therapies for the treatment of severe diseases. The company was founded in 2015 by Dr. Jasmine Cui with the goal of developing innovative therapies that improve patients' lives and advance medical progress. InnoCare has become a key player in the biopharmaceutical industry in China since its establishment and has been listed on the Hong Kong Stock Exchange since 2019. The company has a diversified business model, with a focus on research and development, product marketing and licensing, and collaboration with other companies to develop new therapies. InnoCare specializes in various therapeutic areas, including oncology, immunology, neurology, and dermatology. The company has a wide portfolio of products in clinical development, including small molecules and antibodies that aim to meet unmet medical needs of patients. One of InnoCare's most promising products is ICP-192, a small molecule that can be used to treat various types of cancer. ICP-192, developed by InnoCare itself, is currently in phase III clinical trials. Other important products of InnoCare include ICP-151, a small molecule for treating chronic respiratory diseases, ICP-105, an antibody for treating severe autoimmune diseases, and ICP-601, a small molecule for treating skin inflammation and psoriasis. InnoCare has also entered into several strategic partnerships to expand its growth opportunities and product portfolio. One of these partnerships is collaboration with Roche for the development of ICP-192. InnoCare has also entered into a cooperation agreement with Sanofi for the development of ICP-105 and a licensing agreement with Novartis for the marketing of ICP-151 in China. InnoCare Pharma Ltd is an emerging company in the biopharmaceutical industry, focusing on the development and marketing of innovative therapies for the treatment of severe diseases. The company has a diversified business model based on research and development, product marketing and licensing, and collaboration with other companies for the development of new therapies. With a wide portfolio of products in clinical development and strategic partnerships with renowned companies, InnoCare has great potential for further growth and success in the future. InnoCare Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing InnoCare Pharma's Equity

InnoCare Pharma's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding InnoCare Pharma's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating InnoCare Pharma's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

InnoCare Pharma's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in InnoCare Pharma’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about InnoCare Pharma stock

What is the equity of InnoCare Pharma this year?

InnoCare Pharma has equity of 7.6 B CNY this year.

What was the equity of InnoCare Pharma compared to the previous year?

The equity of InnoCare Pharma has increased/decreased by 35.55% increased compared to the previous year.

What impact does a high equity have on investors of InnoCare Pharma?

A high equity is advantageous for investors of InnoCare Pharma as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of InnoCare Pharma?

A low equity can be a risk for investors of InnoCare Pharma, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of InnoCare Pharma affect the company?

An increase in equity of InnoCare Pharma can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of InnoCare Pharma affect the company?

A reduction in equity of InnoCare Pharma can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of InnoCare Pharma?

Some factors that can affect the equity of InnoCare Pharma include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of InnoCare Pharma so important for investors?

The equity of InnoCare Pharma is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can InnoCare Pharma take to change the equity?

To change equity, InnoCare Pharma can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does InnoCare Pharma pay?

Over the past 12 months, InnoCare Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, InnoCare Pharma is expected to pay a dividend of 0 CNY.

What is the dividend yield of InnoCare Pharma?

The current dividend yield of InnoCare Pharma is .

When does InnoCare Pharma pay dividends?

InnoCare Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of InnoCare Pharma?

InnoCare Pharma paid dividends every year for the past 0 years.

What is the dividend of InnoCare Pharma?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is InnoCare Pharma located?

InnoCare Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von InnoCare Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of InnoCare Pharma from 11/10/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 11/10/2024.

When did InnoCare Pharma pay the last dividend?

The last dividend was paid out on 11/10/2024.

What was the dividend of InnoCare Pharma in the year 2023?

In the year 2023, InnoCare Pharma distributed 0 CNY as dividends.

In which currency does InnoCare Pharma pay out the dividend?

The dividends of InnoCare Pharma are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von InnoCare Pharma

Our stock analysis for InnoCare Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of InnoCare Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.